/PRNewswire/ Nektar Therapeutics (Nasdaq: NKTR) today announced a new strategic plan focused on prioritizing key research and development efforts that will.
/PRNewswire/ Nektar Therapeutics (Nasdaq: NKTR) today announced a new strategic plan focused on prioritizing key research and development efforts that will.
Biolojic Design will conduct the trial for cancer patients in Australia with a new type of drug that makes full use of computational biology and big data
/PRNewswire/ Biolojic Design, a unique technology company pioneering computational design of human antibodies to develop smart therapeutic solutions for.